|
|
 |
|
Viewing report
|
|
|
|
Alnylam Pharmaceuticals, Inc (ALNY) - Financial and Strategic SWOT Analysis Review
GlobalData, April 2012, Pages: 46
Alnylam Pharmaceuticals, Inc (ALNY) - Financial and Strategic SWOT Analysis Review
Summary
Alnylam Pharmaceuticals, Inc., (Alnylam) is a biopharmaceutical company focusing on the discovery, development and commercialization of novel therapeutics based on Ribo Nucleic Acid interference (RNAi). The company is primarily involved in its Alnylam 5x15 program for developing RNAi based therapeutics targeted against genetically defined diseases. Alnylam has five products in various clinical development stages under this program, namely, ALN-TTR (for the treatment of transthyretin-mediated amyloidosis (ATTR)), ALN-PCS (for the treatment of hypercholesterolemia), ALN-HPN (for the treatment of refractory anemia), ALN-APC (for the treatment of hemophilia), and ALN-TMP (for the treatment of treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia). In addition, the company is also indulged in the development of three partner programs which include ALN-RSV (for the treatment of RSV infection), ALN-VSP (for the treatment of liver cancer), and ALN-HTT (for the treatment of Huntington’s disease). The company has various platform, discovery and development, and product alliances with Medtronic, Inc.; Novartis Pharma AG; Biogen Idec, Inc.; F. Hoffman –La Roche Ltd., Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company has a Biotherapeutics division, Alnylam Biotherapeutics, focused on development of RNAi technologies such as VaxiRNA technology with applications in vaccine and other biologics manufacturing processes. Alnylam is headquartered in Cambridge, Massachusetts, the US.
The company’s key business strategies involve successful development of its product pipeline targeted towards disorders with high unmet needs and protecting these products through various patents. This intent is indicated from various research collaborations signed by the company (including Arrowhead Research Corporation, GlaxoSmithKline) as well as clinical trials applications signed with Medicines and Healthcare products Regulatory agency for ALN-TTR02 in the recent past.
Alnylam Pharmaceuticals, Inc Key Recent Developments
Mar 14, 2012: Alnylam Retains Key Claims For Kinesin Spindle Protein RNAi Patent In Interference Proceedings
Mar 01, 2012: Alnylam And University Of Massachusetts Medical School Announce Tuschl I Patent Upheld In European Opposition Proceedings
Feb 09, 2012: Alnylam Pharmaceuticals Reports Revenue Of $20.5m In Q4 2011
Feb 09, 2012: Alnylam Scientists Discover New Method For Monitoring RNAi Activity In Blood Samples
Jan 30, 2012: Alnylam Receives Notice Of Allowance From USPTO For New Patent Broadly Covering Second Generation Lipid Nanoparticle Platform
This comprehensive SWOT profile of Alnylam Pharmaceuticals, Inc provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
Alnylam Pharmaceuticals, Inc - Product Pipeline Review - H2 2011
Tekmira Pharmaceuticals Corp. (TKM) - Financial and Strategic SWOT Analysis Review
Tekmira Pharmaceuticals Corp. - Product Pipeline Review - H2 2011
Tekmira Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010
Tekmira Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010
Tekmira Pharmaceuticals Corp. - Product Pipeline Review - Q1 2011
Alnylam Pharmaceuticals, Inc - Product Pipeline Review - Q4 2010
GlaxoSmithKline plc (GSK) - Financial and Strategic SWOT Analysis Review
Syneron Medical Ltd. (ELOS) - Financial and Strategic SWOT Analysis Review
Life Technologies Corporation (LIFE) - Financial and Strategic SWOT Analysis Review
|
|
|
|
